CATALOGO DEI PRODOTTI DELLA RICERCA

MAURELLI, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.065
EU - Europa 2.896
AS - Asia 2.302
SA - Sud America 285
AF - Africa 107
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.673
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.984
RU - Federazione Russa 1.261
SG - Singapore 890
CN - Cina 447
IT - Italia 421
GB - Regno Unito 250
HK - Hong Kong 235
BR - Brasile 233
DE - Germania 226
VN - Vietnam 189
FR - Francia 153
IE - Irlanda 152
FI - Finlandia 115
SE - Svezia 115
IN - India 96
JP - Giappone 78
KR - Corea 77
BD - Bangladesh 63
ES - Italia 49
ID - Indonesia 46
CA - Canada 42
NL - Olanda 40
IQ - Iraq 37
SA - Arabia Saudita 32
TR - Turchia 27
TG - Togo 25
UA - Ucraina 21
AR - Argentina 20
MX - Messico 20
AT - Austria 19
BJ - Benin 19
BE - Belgio 17
NG - Nigeria 16
EG - Egitto 13
ZA - Sudafrica 13
AU - Australia 11
PL - Polonia 11
PK - Pakistan 10
EC - Ecuador 8
IL - Israele 8
IR - Iran 8
HU - Ungheria 7
MY - Malesia 7
PH - Filippine 7
TW - Taiwan 6
AL - Albania 5
CL - Cile 5
CR - Costa Rica 5
GR - Grecia 5
KE - Kenya 5
MA - Marocco 5
UY - Uruguay 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
BG - Bulgaria 4
CH - Svizzera 4
NZ - Nuova Zelanda 4
VE - Venezuela 4
BH - Bahrain 3
CO - Colombia 3
CZ - Repubblica Ceca 3
GT - Guatemala 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
LT - Lituania 3
OM - Oman 3
PE - Perù 3
TN - Tunisia 3
AG - Antigua e Barbuda 2
BN - Brunei Darussalam 2
BO - Bolivia 2
DK - Danimarca 2
DM - Dominica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
NI - Nicaragua 2
NP - Nepal 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
ET - Etiopia 1
GF - Guiana Francese 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
KG - Kirghizistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
Totale 8.665
Salva come PNG Salva come JPEG
Città #
Dallas 634
Singapore 451
Moscow 440
San Jose 410
Ashburn 386
Chandler 244
Hong Kong 227
Dublin 139
Council Bluffs 118
Verona 118
Munich 112
Beijing 102
The Dalles 89
New York 87
Southend 87
Ho Chi Minh City 73
Helsinki 69
Los Angeles 64
London 46
Jacksonville 43
Hanoi 37
Milan 35
Lawrence 34
Princeton 34
Paris 32
Lappeenranta 31
Buffalo 30
Jakarta 30
Redondo Beach 30
Wilmington 28
São Paulo 27
Rome 26
Amsterdam 25
Lomé 25
Chennai 24
Frankfurt am Main 22
Manchester 22
Santa Clara 22
Tokyo 22
Riyadh 21
Madrid 20
Sindelfingen 20
Woodbridge 20
Cotonou 19
Washington 19
Houston 18
Najaf 18
Bologna 17
Jinan 17
Mumbai 17
Monza 16
Seattle 16
Abuja 15
Chicago 14
Nuremberg 14
Orem 14
Shanghai 14
Boston 13
Haiphong 13
Barcelona 12
Phoenix 12
Bethnal Green 11
Ghaziabad 11
Nanjing 11
Warsaw 11
Ann Arbor 10
Atlanta 10
Guangzhou 10
Liverpool 10
Montreal 10
Ankara 8
Brasília 8
Brussels 8
Dongguan 8
Islington 8
Redwood City 8
Tianjin 8
Toronto 8
Vancouver 8
Bari 7
Chieri 7
City of London 7
Fairfield 7
Giza 7
Marseille 7
Mexico City 7
Naples 7
Vienna 7
Wakabadai 7
Baghdad 6
Brooklyn 6
Budapest 6
Delhi 6
Gurugram 6
Hyderabad 6
Igusa 6
Istanbul 6
Jyväskylä 6
Liège 6
Miami 6
Totale 5.136
Salva come PNG Salva come JPEG
Nome #
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 350
A systematic review of treatments for pityriasis lichenoides 339
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study 263
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 229
Gender perspective in the management of psoriasis 190
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study 177
BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. 176
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 172
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 169
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 166
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 157
A case of genital primary syphilis with superimposed impetigo 156
Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature 152
Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis 147
Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature 146
A man with a widespread bullous eruption 135
Amicrobial Pustulosis of the Folds: Report of Three New Cases 135
Advanced Glycation End Products and Psoriasis 134
Neutrophilic figurate erythema: report of a new case in an adult and comparison between adult and paediatric cases 134
Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study 133
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis 131
Annular Erythema: New and Revisited Variants 131
Idiopathic lichenoid and granulomatous dermatitis 130
Adrenergic urticaria successfully treated with omalizumab 129
Uncommon Non‑Infectious Annular Dermatoses 127
Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis 127
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease 127
Clinical profile and co-infections of urethritis in males 126
Price variability of TNF-α inhibitor biosimilars among European countries 119
Biological agents targeting interleukin-13 for atopic dermatitis 117
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 116
Safety and Efectiveness of Upadacitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis Who Smoke: a 2‐Year Real‐Life Multicenter Study 113
Interferon-beta injection site reactions in patients with multiple sclerosis. 113
Atopic Dermatitis in the Elderly Population 112
Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series 112
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis 111
Managing the Patient with Psoriasis and Metabolic Comorbidities 104
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes 103
Milia-like calcinosis cutis in Down syndrome: a new case with a review of the literature 103
Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination 102
Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients 101
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review 101
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients 100
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo 97
Long‑Term Effectiveness and Safety of Ixekizumab for the Treatment of moderate‑to‑Severe Plaque Psoriasis: A Five‑Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 95
Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab 95
Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin 93
Eosinophilic annular erythema successfully treated with cyclosporine 90
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines 88
The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases 85
Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis) 80
null 80
Pruritus as a Distinctive Feature of Type 2 Inflammation 80
Palisaded neutrophilic granulomatous dermatitis and its associations with autoimmune diseases 79
Visual Vignette 79
Targeting IL-4 for the Treatment of Atopic Dermatitis 78
Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle 77
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 76
Tailored biological treatment for patients with moderate-to-severe psoriasis 75
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience 72
Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment 72
Efcacy and safety of JAK inhibitors in patients aged >60 years with moderate‐to‐severe atopic dermatitis: a 52‐week multicenter, real‐life study—IL AD (Italian Landscape Atopic Dermatitis) 69
Is risankizumab as needed administration a good option for patients with plaque psoriasis? 68
Overview of Atopic Dermatitis in Different Ethnic Groups 67
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS) 67
The Combination of Dupilumab with Other Monoclonal Antibodies 67
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260‐Week Real‐World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) 65
Lymphoplasmacytic plaque effectively treated with imiquimod 60
FARMACOECONOMIA APPLICATA ALLE MALATTIE INFIAMMATORIE CRONICHE CUTANEE (PSORIASI E DERMATITE ATOPICA) 58
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis 57
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 57
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 55
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis 51
Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study 45
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations 41
Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study 25
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis 22
The Girl with a Pearl Earring: A dermatological puzzle 20
Klinische Merkmale und Behandlungen der transitorischen akantholytischen Dermatose (Morbus Grover): ein systematischer Review 17
Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence 15
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis) 13
Real‑World Efficacy of IL‑23 Inhibitors in Psoriasis Affecting High‑Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) 11
Dermatologic manifestations in an adult with Williams syndrome 7
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis) 5
Biosimilars for chronic plaque psoriasis: a 2026 update 5
Real-world comparison of IL-23 inhibitors in moderate-to-severe plaque psoriasis: a focus on super responders—IL PSO (Italian landscape Psoriasis) 5
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate‐to‐Severe Atopic Dermatitis: A Multicentre Real‐World Study: IL‐AD (Italian Landscape Atopic Dermatitis) 3
Totale 8.781
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.862
article - articoli 31.173
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 196
patent - brevetti 0
selected - selezionate 0
volume - volumi 493
Totale 63.724
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 0 0 0 0 0 0 10
2021/2022228 13 26 0 18 31 6 6 23 4 14 30 57
2022/2023738 38 68 63 134 58 187 16 34 90 13 25 12
2023/2024647 16 30 56 51 52 126 115 42 8 39 71 41
2024/20251.894 119 63 98 291 80 115 168 111 244 136 143 326
2025/20264.918 293 169 674 610 1.141 273 428 293 340 392 137 168
Totale 8.781